Le Lézard
Classified in: Covid-19 virus
Subject: ATY

The Gross Law Firm Notifies Amplitude, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMPL


NEW YORK, April 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. (NASDAQ: AMPL).

Shareholders who purchased shares of AMPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/amplitude-loss-submission-form/?id=75204&from=4 

CLASS PERIOD: September 21, 2021 to February 16, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Amplitude's land-and-expand strategy was years away from significantly accelerating revenues among its newer client cohorts; (b) the rapid acceleration in the Company's 2Q21 results resulted from the ephemeral effects of the COVID-19 pandemic which had not continued by the start of the class period, as Amplitude clients were expanding at a slower pace; and (c) as a result of (a)-(b) above, Amplitude's business, operations, financial results, and prospects were materially worse than represented to investors during the class period.

DEADLINE: April 15, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/amplitude-loss-submission-form/?id=75204&from=4 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of AMPL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 15, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 09:35
Red Pine Exploration Inc.  ("Red Pine" or the "Company"), further to its press releases of May 1, 2024, and May 6, 2024 (the "Prior Press Releases"), provides a further update on the Company's progress on its investigations into the reporting...

at 09:05
Hyperfine, Inc. , the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system?the Swoop® system?today announced it has entered into agreements with...

at 09:00
Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq...

at 08:30
Xenetic Biosciences, Inc. ("Xenetic" or the "Company"), a biopharmaceutical...

at 08:30
BioLargo, Inc. , a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced it will host an investor webcast and conference call on Tuesday, May 14, 2024, at 2:30 pm Pacific /...

at 08:00
PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment Letter ("AAL") for its Priority Original Abbreviated New Drug Application ("ANDA") for Ketamine...



News published on and distributed by: